Peter J Selby

发表

Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours

W. Gregory, P. Selby, J. Cartledge, 2013, BJU international.

Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro.

Jennifer Southgate, J. Southgate, G. Hill, 2005, Experimental cell research.

Genome-wide association study identifies multiple risk loci for renal cell carcinoma

Bin Tean Teh, Tony Fletcher, Peter Kraft, 2017, Nature Communications.

Variation in genomic landscape of clear cell renal cell carcinoma across Europe

Edgars Celms, Martins Opmanis, Andris Zarins, 2014, Nature Communications.

Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison

John K Field, Lucinda J Billingham, David A Cairns, 2009, Proteomics.

Resistance to the Tubulin-Binding Agents in Renal Cell Carcinoma: No Mutations in the Class I β-Tubulin Gene but Changes in Tubulin Isotype Protein Expression

Rosamonde E Banks, C. Taylor, P. Selby, 2005, Clinical Cancer Research.

Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma

Rosamonde E Banks, D. Pappin, D. Rahman, 2003, Proteomics.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

G. Morgan, M. Drayson, F. Davies, 2003, The New England journal of medicine.

Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3

Paolo Vineis, Salvatore Panico, Vittorio Krogh, 2011, Nature Genetics.

Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma

Richard Unwin, Ian Eardley, Rosamonde E Banks, 2006, Proteomics.

Proteomics: new perspectives, new biomedical opportunities

Jean-Charles Sanchez, Denis F Hochstrasser, Darryl J Pappin, 2000, The Lancet.

Renal cancer biomarkers: the promise of personalized care

Rosamonde E Banks, N. Vasudev, P. Selby, 2012, BMC Medicine.

The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer

Jenny Hewison, Helen Howard, Catherine Lowe, 2012, BMC Cancer.

Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies

Rosamonde E Banks, A. Harris, P. Selby, 2005, Proteomics.